Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Jiangsu Kanion Pharmaceutical Co. Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, indicating that the company's current patenting efforts cover different technical aspects of the pharmaceutical field. This distribution prevents the portfolio's progress from being entirely dependent on a single examiner. Engaging with 2 distinct art units allows the company to protect its innovations across different specialized sections of the USPTO.
The busiest examiner, MOORE, SUSANNA, is responsible for 1 pending office action. Given that there are 2 pending office actions in total, the workload is split among the examiners. This balanced approach allows the company to navigate the requirements of multiple art units while receiving feedback from different examiners. The remaining 1 pending office action is handled by another examiner, ensuring that the company's pharmaceutical-related intellectual property is not subject to the review of only a single individual.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| BARRERA, IMMACULADA | 1 | 30.0% | +80.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554972 | RECOMBINANT NEWCASTLE DISEASE VIRUS RNDV-VEGF-TRAP, GENOME THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | BARRERA, IMMACULADA | 23d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554972 | RECOMBINANT NEWCASTLE DISEASE VIRUS RNDV-VEGF-TRAP, GENOME THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | BARRERA, IMMACULADA | 23d |
| 18704441 | 5-SUBSTITUTED PYRIDINE-2(1H)-KETONE COMPOUND AND USE THEREOF | MOORE, SUSANNA | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704441 | 5-SUBSTITUTED PYRIDINE-2(1H)-KETONE COMPOUND AND USE THEREOF | MOORE, SUSANNA | 1624 | §112DP | Final Rejection | — | Pending | Apr 24, 2024 |
| 18554972 | RECOMBINANT NEWCASTLE DISEASE VIRUS RNDV-VEGF-TRAP, GENOME THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | BARRERA, IMMACULADA | 1671 | §103§112Other | Final Rejection | 23d | Pending | Oct 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJiangsu Kanion Pharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Susanna Moore has the most, with 1 of Jiangsu Kanion Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
